Genistein represses PEPCK-C expression in an insulin-independent manner in HepG2 cells and in alloxan-induced diabetic mice

Barilin Dkhar, Kitboklang Khongsti, Daiahun Thabah, Donkupar Syiem, Kapaettu Satyamoorthy, Bidyadhar Das

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    Genistein has been reported to exert beneficial effects on type 2 diabetes mellitus (T2DM); however, the underlying molecular mechanisms involved therein have not been clearly elucidated. To address this question, the effect of genistein on the expression of phosphoenolpyruvate carboxykinase (PEPCK), and glucose production in HepG2 cells and in alloxan-induced diabetic mice was investigated. HepG2 cells were exposed to different concentration of genistein in presence or absence of modulators, and the expression of cytosolic PEPCK (PEPCK-C) and the signaling pathways was studied. Further, the biological relevance of the in vitro study was tested in alloxan-induced diabetic mice. Genistein lowered PEPCK-C expression and glucose production in HepG2 cells accompanied with increased in phosphorylation states of AMPK, MEK1/2, ERK1/2, and CRTC2. Treatment with the AMPK inhibitor (compoundC) enhanced genistein-induced MEK1/2 and ERK1/2 activity indicating a potential cross-talk between the two signaling pathways. In vivo, genistein also reduced fasting glucose levels accompanied with reduced PEPCK-C expression and increased in AMPK and ERK1/2 phosphorylation states in the liver of genistein-treated alloxan-induced diabetic mice. Genistein fulfills the criteria of a suitable anti-diabetic agent by reducing glucose production and inhibiting PEPCK-C expression in HepG2 cells and also in alloxan-induced diabetic mice. These results indicate that genistein is an effective candidate for preventing T2DM through the modulation of AMPK-CRTC2 and MEK/ERK signaling pathways, which may allow a novel approach to modulate dysfunction in hepatic gluconeogenesis in T2DM.

    Original languageEnglish
    JournalJournal of Cellular Biochemistry
    DOIs
    Publication statusAccepted/In press - 2017

    Fingerprint

    Alloxan
    Phosphoenolpyruvate
    Genistein
    Hep G2 Cells
    Insulin
    AMP-Activated Protein Kinases
    Medical problems
    Type 2 Diabetes Mellitus
    Glucose
    Phosphorylation
    Gluconeogenesis
    MAP Kinase Signaling System
    Liver
    Reducing Agents
    Mitogen-Activated Protein Kinase Kinases
    Modulators
    Fasting
    Modulation

    All Science Journal Classification (ASJC) codes

    • Biochemistry
    • Molecular Biology
    • Cell Biology

    Cite this

    @article{095f57fdef8b4c969c30079c6b4aaf19,
    title = "Genistein represses PEPCK-C expression in an insulin-independent manner in HepG2 cells and in alloxan-induced diabetic mice",
    abstract = "Genistein has been reported to exert beneficial effects on type 2 diabetes mellitus (T2DM); however, the underlying molecular mechanisms involved therein have not been clearly elucidated. To address this question, the effect of genistein on the expression of phosphoenolpyruvate carboxykinase (PEPCK), and glucose production in HepG2 cells and in alloxan-induced diabetic mice was investigated. HepG2 cells were exposed to different concentration of genistein in presence or absence of modulators, and the expression of cytosolic PEPCK (PEPCK-C) and the signaling pathways was studied. Further, the biological relevance of the in vitro study was tested in alloxan-induced diabetic mice. Genistein lowered PEPCK-C expression and glucose production in HepG2 cells accompanied with increased in phosphorylation states of AMPK, MEK1/2, ERK1/2, and CRTC2. Treatment with the AMPK inhibitor (compoundC) enhanced genistein-induced MEK1/2 and ERK1/2 activity indicating a potential cross-talk between the two signaling pathways. In vivo, genistein also reduced fasting glucose levels accompanied with reduced PEPCK-C expression and increased in AMPK and ERK1/2 phosphorylation states in the liver of genistein-treated alloxan-induced diabetic mice. Genistein fulfills the criteria of a suitable anti-diabetic agent by reducing glucose production and inhibiting PEPCK-C expression in HepG2 cells and also in alloxan-induced diabetic mice. These results indicate that genistein is an effective candidate for preventing T2DM through the modulation of AMPK-CRTC2 and MEK/ERK signaling pathways, which may allow a novel approach to modulate dysfunction in hepatic gluconeogenesis in T2DM.",
    author = "Barilin Dkhar and Kitboklang Khongsti and Daiahun Thabah and Donkupar Syiem and Kapaettu Satyamoorthy and Bidyadhar Das",
    year = "2017",
    doi = "10.1002/jcb.26356",
    language = "English",
    journal = "Journal of Cellular Biochemistry",
    issn = "0730-2312",
    publisher = "Wiley-Liss Inc.",

    }

    Genistein represses PEPCK-C expression in an insulin-independent manner in HepG2 cells and in alloxan-induced diabetic mice. / Dkhar, Barilin; Khongsti, Kitboklang; Thabah, Daiahun; Syiem, Donkupar; Satyamoorthy, Kapaettu; Das, Bidyadhar.

    In: Journal of Cellular Biochemistry, 2017.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Genistein represses PEPCK-C expression in an insulin-independent manner in HepG2 cells and in alloxan-induced diabetic mice

    AU - Dkhar, Barilin

    AU - Khongsti, Kitboklang

    AU - Thabah, Daiahun

    AU - Syiem, Donkupar

    AU - Satyamoorthy, Kapaettu

    AU - Das, Bidyadhar

    PY - 2017

    Y1 - 2017

    N2 - Genistein has been reported to exert beneficial effects on type 2 diabetes mellitus (T2DM); however, the underlying molecular mechanisms involved therein have not been clearly elucidated. To address this question, the effect of genistein on the expression of phosphoenolpyruvate carboxykinase (PEPCK), and glucose production in HepG2 cells and in alloxan-induced diabetic mice was investigated. HepG2 cells were exposed to different concentration of genistein in presence or absence of modulators, and the expression of cytosolic PEPCK (PEPCK-C) and the signaling pathways was studied. Further, the biological relevance of the in vitro study was tested in alloxan-induced diabetic mice. Genistein lowered PEPCK-C expression and glucose production in HepG2 cells accompanied with increased in phosphorylation states of AMPK, MEK1/2, ERK1/2, and CRTC2. Treatment with the AMPK inhibitor (compoundC) enhanced genistein-induced MEK1/2 and ERK1/2 activity indicating a potential cross-talk between the two signaling pathways. In vivo, genistein also reduced fasting glucose levels accompanied with reduced PEPCK-C expression and increased in AMPK and ERK1/2 phosphorylation states in the liver of genistein-treated alloxan-induced diabetic mice. Genistein fulfills the criteria of a suitable anti-diabetic agent by reducing glucose production and inhibiting PEPCK-C expression in HepG2 cells and also in alloxan-induced diabetic mice. These results indicate that genistein is an effective candidate for preventing T2DM through the modulation of AMPK-CRTC2 and MEK/ERK signaling pathways, which may allow a novel approach to modulate dysfunction in hepatic gluconeogenesis in T2DM.

    AB - Genistein has been reported to exert beneficial effects on type 2 diabetes mellitus (T2DM); however, the underlying molecular mechanisms involved therein have not been clearly elucidated. To address this question, the effect of genistein on the expression of phosphoenolpyruvate carboxykinase (PEPCK), and glucose production in HepG2 cells and in alloxan-induced diabetic mice was investigated. HepG2 cells were exposed to different concentration of genistein in presence or absence of modulators, and the expression of cytosolic PEPCK (PEPCK-C) and the signaling pathways was studied. Further, the biological relevance of the in vitro study was tested in alloxan-induced diabetic mice. Genistein lowered PEPCK-C expression and glucose production in HepG2 cells accompanied with increased in phosphorylation states of AMPK, MEK1/2, ERK1/2, and CRTC2. Treatment with the AMPK inhibitor (compoundC) enhanced genistein-induced MEK1/2 and ERK1/2 activity indicating a potential cross-talk between the two signaling pathways. In vivo, genistein also reduced fasting glucose levels accompanied with reduced PEPCK-C expression and increased in AMPK and ERK1/2 phosphorylation states in the liver of genistein-treated alloxan-induced diabetic mice. Genistein fulfills the criteria of a suitable anti-diabetic agent by reducing glucose production and inhibiting PEPCK-C expression in HepG2 cells and also in alloxan-induced diabetic mice. These results indicate that genistein is an effective candidate for preventing T2DM through the modulation of AMPK-CRTC2 and MEK/ERK signaling pathways, which may allow a novel approach to modulate dysfunction in hepatic gluconeogenesis in T2DM.

    UR - http://www.scopus.com/inward/record.url?scp=85033599912&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85033599912&partnerID=8YFLogxK

    U2 - 10.1002/jcb.26356

    DO - 10.1002/jcb.26356

    M3 - Article

    JO - Journal of Cellular Biochemistry

    JF - Journal of Cellular Biochemistry

    SN - 0730-2312

    ER -